Targeting sirtuin-1 alleviates experimental autoimmune colitis by induction of Foxp3+ T-regulatory cells

T Akimova1, H Xiao2, Y Liu1, TR Bhatti1, J Jiao2, E Eruslanov3, S Singhal3, L Wang1, R Han1, K Zacharia2, WW Hancock1 and UH Beier2

Induced Forkhead box P3-positive (Foxp3+) T-regulatory cells (iTregs) are essential to gastrointestinal immune homeostasis, and loss of the ability to develop iTregs may lead to autoimmune colitis. We previously showed a role for sirtuin-1 (Sirt1) in control of Treg function and hypothesized that targeting of Sirt1 might enhance iTreg development and thereby represent a potential therapy for inflammatory bowel disease (IBD). We adoptively transferred CD4+CD25−/−Foxp3−/−T effector (TE) cells from wild-type (WT) (C57BL/6) or fl-Sirt1/CD4cre mice into B6/Rag1−/− mice and monitored the mice until they lost 10–15% of their weight. Adoptive transfer of TE cells lacking Sirt1 to B6/Rag1−/− mice resulted in a 2.8-fold increase in iTreg formation compared with mice receiving WT TE cells and correlated with attenuated colitis and reduced weight loss (1.04 ± 1.4% vs. 13.97 ± 2.2%, respectively, \( P < 0.001 \)). In a second model of IBD, we used pharmacologic Sirt1 targeting of mice receiving multiple cycles of dextran sodium sulfate (DSS) in their drinking water, alternated with fresh water. Likewise, WT mice receiving cyclic DSS and a Sirt1 inhibitor, EX-527, had reduced weight loss (5.8 ± 5.9% vs. 13.2 ± 6.9%, respectively, \( P = 0.03 \)) and increased iTreg formation compared with controls. Sirt1 appears a promising target for pharmacologic therapy of IBD as a result of promoting iTreg development.

INTRODUCTION

Intestinal immune homeostasis must encompass effective defense against pathogens but tolerance to antigens from food and commensals. Therefore, the gastrointestinal tract maintains a highly active and specialized immune system capable of activation or attenuation in response to specific antigens.1,2 T-regulatory cells (Tregs) are central to intestinal immune tolerance and are considered a potential therapeutic target in inflammatory bowel disease (IBD).2,3 Tregs developing in the thymus are known as natural Treg cells (nTregs), whereas those developing from conventional T cells are termed induced Treg cells (iTregs).4 Both nTregs and iTregs are characterized by expression of the transcription factor Forkhead box P3 (Foxp3) that is essential to their suppressive function.5,6 Humans with mutations in the Foxp3 gene suffer from autoimmune diseases such as colitis, underlining the importance of Tregs for intestinal homeostasis.7 However, many patients suffering from IBD have increased rather than decreased numbers of Foxp3+ Tregs,8,9 leading to the suggestion that it is not the overall number of Foxp3+ Tregs, but the formation of iTregs that is essential to intestinal immune homeostasis, similar to their role in oral tolerance.2,10 Josefowicz et al.11 found that mice lacking the Foxp3 enhancer CNS1 (conserved noncoding sequence 1), which are unable to develop iTregs but have normal nTreg development and function, exhibit pronounced inflammation at mucosal sites such as the gastrointestinal and respiratory tracts. Furthermore, mice that lack the tumor growth factor–β-Smad response element within the CNS1 region have normal Treg development, except within the gastrointestinal tract.12 These data support a model in which iTreg formation is central to intestinal homeostasis. Therefore, therapies that promote iTreg formation might be of therapeutic benefit in IBD.
We have previously shown that targeting sirtuin-1 (Sirt1) by genetic deletion or pharmacologic inhibition led to increased Treg-suppressive function *in vitro* and *in vivo* and prolonged allograft survival.\(^{13,14}\) Sirt1 is an nicotinamide adenine dinucleotide-dependent class III histone/protein deacetylase highly conserved across eukaryotic species, which regulates important processes in cell physiology by catalyzing \(\epsilon\)-acetyl-lysine deacetylation of histones (facilitating chromatin condensation) and multiple nonhistone proteins.\(^{15}\) Among those nonhistone proteins is Foxp3. Blocking Sirt1 increases Foxp3 acetylation, thereby increasing Treg function.\(^{13,16-18}\) However, the effects of Sirt1 targeting on nTregs vs. iTregs remain uncertain. As adoptive transfer models of colitis with immunodeficient (B6/Rag1\(^{-/-}\)) mice provide a good opportunity to discern the effects of thymic vs. *in vivo* Tregs, we studied whether Sirt1 targeting could be specifically beneficial for iTregs and therefore of therapeutic interest for inflammatory diseases of the gastrointestinal tract.

### RESULTS

**Loss of Sirt1 promotes Foxp3\(^{+}\) iTreg formation and attenuates autoimmune colitis**

We injected intravenously \(5 \times 10^7\) highly purified T effector (TE) cells, isolated from WT or fl-Sirt1/CD4cre mice, into 12-week-old B6/Rag1\(^{-/-}\) mice and assessed the development of colitis. B6/Rag1\(^{-/-}\) mice adoptively transferred with TE cells lacking Sirt1 had significantly less weight loss than mice receiving WT Tregs (*Figure 1a, b*). We observed this pattern persistently over four independent experiments with a total of 34 mice. Similarly, adoptive transfer of TE cells into 6-week-old B6/Rag1\(^{-/-}\) mice led to disruption of somatic growth if the TE cells originated from WT mice, but not from fl-Sirt1/CD4cre mice (\(n = 10\); Supplementary Figure S1 online). B6/Rag1\(^{-/-}\) mice receiving fl-Sirt1/CD4cre TE developed less splenomegaly than WT TE recipients (*Figure 1c, d*). Consistent with weight loss and splenomegaly, WT TE recipients developed much more severe colitis upon histology in comparison with fl-Sirt1/CD4cre TE recipients (*Figure 1e-g*).

We used immunohistochemistry of CD3 expression to assess T-cell infiltration within colon sections. We found that B6/Rag1\(^{-/-}\) mice adoptively transferred with WT TE cells had significantly more infiltrating T cells in the colonic mucosa than fl-Sirt1/CD4cre recipients (*Figure 2a, b*). Furthermore, we noted decreased CD4, interleukin-6 (IL-6), and IL-17 mRNA expression in colon samples from B6/Rag1\(^{-/-}\) mice whose adoptively transferred TE were lacking Sirt1 (*Figure 2c-e*). Hence, absence of Sirt1 resulted in less T-cell infiltration into colonic tissues.

Given previous data on the role of Sirt1 in Treg stability,\(^{13,16}\) we assessed the numbers of Foxp3\(^{+}\) Tregs within mesenteric lymph nodes and spleens. We found that B6/Rag1\(^{-/-}\) recipients of fl-Sirt1/CD4cre TE had more Foxp3\(^{+}\) Tregs as recipients of WT TE cells, for both spleens and mesenteric lymph nodes (*Figure 3a, b*, left panels). The presence of these Tregs raised several questions: Are Tregs observed at the end of the study *de novo* induced from naive T cells? Furthermore, how can the differences in inflammatory responses be explained? Is the increased number of Tregs, their lack of Sirt1, or differences in TE function (due to the lack of Sirt1) responsible for the alleviation of colitis?

To ensure that the Foxp3\(^{+}\) Tregs observed at the end of the experiment were *de novo* iTregs and not already committed Tregs originating from the injection of splenocytes, we depleted CD25\(^{+}\) cells from the injected cells with a modified cell separation protocol and achieved equal 99% Foxp3\(^{+}\) purity in both WT and fl-Sirt1/CD4cre TE cells (Supplementary Figure S2). Furthermore, to exclude possible overgrowth of nTregs in the fl-Sirt1/CD4cre TE-treated mice, we assessed cell proliferation through Ki-67 expression in Foxp3\(^{+}\) Tregs at the end of the experiment, which was equal between WT and fl-Sirt1/CD4cre TE-injected mice (Supplementary Figure S3). Therefore, it seems plausible that the observed Foxp3\(^{+}\) Tregs at the end of the experiment are iTregs, and that fl-Sirt1/CD4cre TE may have a tendency to convert more easily to become iTregs.

Although increased iTreg formation may explain the better disease outcome we observed in Rag1\(^{-/-}\) mice receiving fl-Sirt1/CD4cre TE, it is also possible to speculate that fl-Sirt1/CD4cre TE cells are inherently less able to cause disease. The degree of splenomegaly, inflammation, and numbers of TE cells on histology suggested that adoptively transferred TE cells lacking Sirt1 may be less inflammatory by their phenotype or were better regulated by Tregs. With regard to TE cell function, we have extensively studied the phenotype of fl-Sirt1/CD4cre TE in *in vivo* and *in vitro* in our previous work, and did not observe any differences in their proliferation or cellular activation.\(^{13}\) To assess if fl-Sirt1/CD4cre TE cells are more susceptible to Treg suppression than WT TE cells, we conducted Treg suppression assays, comparing WT and fl-Sirt1/CD4cre TE cell suppression by WT Tregs. We found that WT and fl-Sirt1/CD4cre TE cells can both be suppressed by Tregs and that there was a trend for fl-Sirt1/CD4cre TE to be slightly more resistant to Treg suppression (*Figure 4a*). Next, we tested cytokine production by freshly isolated CD4\(^{+}\)CD25\(^{+}\) TE activated with phorbol 12-myristate 13-acetate (PMA) and ionomycin. We noted that *in vitro* production of interferon-\(\gamma\) was very similar for both cell populations, although trending higher for fl-Sirt1/CD4cre TE (*Figure 4b*). Conversely, IL-2 production was decreased in fl-Sirt1/CD4cre TE in comparison with WT TE cells (*Figure 4c*). In a previous Parent-to-F1 experiment, we did not notice any difference in cytokine production *in vivo*.\(^{13}\) Overall, our data do not indicate that fl-Sirt1/CD4cre TE cells are more susceptible to Treg-mediated suppression, although they do have decreased IL-2 production upon stimulation *in vitro* when compared with WT cells.

Given that the phenotypic differences between fl-Sirt1/CD4cre and WT TE cells were minimal, we focused our attention on increased iTreg formation in fl-Sirt1/CD4cre TE recipients. The number of iTregs, evaluated in each individual mouse, correlated inversely with weight loss (*Figure 3a, b*, right panel). This combined with our previous data on relatively similar TE function between fl-Sirt1/CD4cre and WT TE cells,
but differences in iTreg levels in correlation with different colitis severity, led us to hypothesize that the difference in disease outcomes is predominately iTreg mediated.

**Figure 1** T effector (TE) cells lacking sirtuin-1 (Sirt1) cause less autoimmune colitis. Twelve-week-old B6/Rag1−/− mice were adoptively transferred with 5 × 10^5 CD4+ CD25− (<1.1% Forkhead box P3-positive (Foxp3+) TEs intravenously of either C57Bl/6 wild-type (WT) or fl-Sirt1/CD4cre (SC) origin and followed until autoimmune colitis developed. Data pooled from four independent experimental setups (n = 34 mice). (a and b) B6/Rag1−/− mice injected with SC TE developed less disease and weight loss. (a) Weight curves, normalized to the end point of each of the four independent experiments. (b) Percent weight loss as boxplots (whiskers: 5th–95th percentile). (c) Smaller spleen size in fl-Sirt1/CD4cre TE-injected B6/Rag1−/− mice. Bar = 1 cm. (d) B6/Rag1−/− mice receiving WT TE cells showed a higher splenocyte count than fl-Sirt1/CD4cre TE recipients. (e) Colonic specimens from B6/Rag1−/− mice receiving WT TE cells show significant colitis including marked crypt architectural distortion (original magnification × 100) with neutrophilic infiltration of the lamina propria, crypt epithelium (“cryptitis”), and glandular lumina (“crypt abscess”, see original magnification × 630). In contrast, adoptive transfer of TE lacking Sirt1 produced much less signs of colitis. Hematoxylin and eosin staining; bar = 200 μm. (f and g) Pooled data from blinded histologic analysis demonstrate less colitis pathology in mice adoptively transferred with fl-Sirt1/CD4cre TE (n = 10).

Tregs are known as bystander suppressors as they can inhibit the activity of virtually any immune cell through cell–cell contacts or remotely by cytokine production. We therefore
assessed cellular activation and proliferation in non-Treg and host non-T cells, using Ki-67 expression as a readout. Ki-67 is a proliferation marker that is present during all active phases of proliferation in cells.

Figure 2 Lack of sirtuin-1 (Sirt1) in T cells leads to decreased T-cell infiltration into the colonic mucosa. (a and b) Immunohistochemistry of CD3 showing decreased T-cell infiltration in Rag1<sup>−/−</sup> mice adoptively transferred with fi-Sirt1/CD4cre (SC) vs. wild-type (WT) T effector (TE) cells, respectively (experimental conditions as in Figure 1). (b) Pooled histologic data from automated slide quantification (n = 10). (c-e) mRNA expression profiles from colonic tissue indicates increased CD4, IL-6, and IL-17 mRNA expression in B6/Rag1<sup>−/−</sup> recipients of WT compared with SC TE (n = 8).

Figure 3 T effector (TE) cells lacking sirtuin-1 (Sirt1) are more susceptible to Forkhead box P3-positive T-regulatory cell (Foxp3<sup>+</sup> Treg) induction in vivo. Pooled analysis of flow cytometry data of experiments from Figure 1. (a) Splenocytes from B6/Rag1<sup>−/−</sup> mice adoptively transferred with fi-Sirt1/CD4cre (SC) TE exhibited an increased fraction of induced Treg (iTreg) (left panel). Weight loss negatively correlated with iTreg conversion (right panel). (b) Similarly, mesenteric lymph nodes (mLN) from B6/Rag1<sup>−/−</sup> mice receiving SC TE tended to have increased Foxp3<sup>+</sup> iTreg (left panel), which is negatively correlated with weight loss (right panel).

Figure 4 Sirtuin-1 (Sirt1) and T effector (TE) function. (a) Comparison of carboxyfluorescein succinimidyl ester (CFSE)-labeled wild-type (WT) (black) or fi-Sirt1/CD4cre (SC) (gray) TE (CD4<sup>+</sup> CD25<sup>−</sup>) to be suppressed by WT T-regulatory cells (Tregs) in vitro, showing near equal susceptibility. TE proliferation indicated by percentage for both WT (black) and SC (gray). Percent of maximum (% of Max) shows normalization of overlaid data and represents the number of cells in each bin divided by the number of cells in the bin that contains the largest number of cells. (b and c) WT and SC TE cells were stimulated with phorbol 12-myristate 13-acetate/ionomycin to elicit cytokine production, showing a trend toward higher (b) interferon-γ (IFN-γ) and (c) decreased interleukin-2 (IL-2) production. Data are representative of three independent experiments.

assessed cellular activation and proliferation in non-Treg and host non-T cells, using Ki-67 expression as a readout. Ki-67 is a proliferation marker that is present during all active phases of...
Mucosal Immunology | VOLUME 7 NUMBER 5 | SEPTEMBER 2014

The cell cycle but is absent in resting cells at the G0 phase.20 Through combination with other flow cytometry parameters, it is possible to judge proliferation of injected TE cells that remained Foxp3− as well as in host cells. Host cells can be identified by gating on CD4−, taking advantage of the fact that B6/Rag1−/− mice lack their own CD4 cells, while injected cells were >99% CD4+ purified (Supplementary Figure S2). We observed that both Foxp3− TE and CD4− host cells expressed less Ki-67 in B6/Rag1−/− recipients that received fl-Sirt1/CD4cre (SC) compared with wild-type (WT) T effector cells (Figure 5a, b). The presence of Ki-67 in both injected CD4+Foxp3− (Figure 5c) and CD4− (Figure 5d) host cells also correlated with individual weight loss. Taken together, our data show that in an adoptive transfer model of colitis, TE cells lacking Sirt1 convert more easily to iTregs and that enhanced iTreg conversion correlated with a model of colitis, TE cells lacking Sirt1 convert more easily to loss. Thus, we noted evidence of a less pronounced inflammatory response by host B6/Rag1−/− immune cells in mice adoptively transferred with fl-Sirt1/CD4cre TE and enhanced iTreg formation in vivo.

Phenotype of iTregs developing during colitis differs from that of nTregs

We next characterized the iTregs observed in our B6/Rag1−/− adoptive TE transfer autoimmune colitis model, and specifically, which is known as (thymic) Treg-associated markers were also expressed by iTregs. We stained splenocytes for CTLA4, CD39, CD127, and CD103 and evaluated their expression in each mouse in conjunction with weight loss. CD39 and CTLA4 expression was increased in WT vs. Sirt1/CD4cre iTregs (Figure 7a, b) and neither correlated with weight loss (not shown). WT TE cells also had significantly upregulated CTLA4 expression (Figure 7b), and CTLA4 expression in TE strongly correlated with their proliferation (% of Ki-67+ in TE: r = 0.898, P = 0.001) and with weight loss (r = 0.920, P = 0.004). These data suggest that in this colitis model, CTLA4 upregulation served as a marker of activated TE cells rather than as a marker of suppressive Tregs. We also noted a strong upregulation of CD39 among the injected TE cells that...
remained Foxp3−, especially within WT TE cells (Figure 7c), and that CD39 expression correlated with more severe weight loss (r = 0.572, P = 0.041). Collectively, these data suggest that CTLA4 and CD39 cannot serve as ‘classical’ Treg-associated markers when evaluated in colitis.

In contrast, expression of CD103 and loss of CD127 proved more useful. CD103 expression by the iTreg population was inversely correlated with divisions of both injected TE cells and host B6/Rag1−/− cells (Ki-67 in CD4+ Foxp3− or CD4− cells), respectively (Figure 7d, e), suggesting that this marker could be relevant to iTreg trafficking and/or function. Accordingly, Ki-67 expression was significantly lower in CD4+ Foxp3− TE cells and in host CD4− cells of mice receiving Sirt1/CD4cre TE cells vs. WT TE cells (Figure 5a, b), indicating less proliferation of TE and host cells in recipients of fl-Sirt1/CD4cre TE. CD103 expression in iTregs also tended to be higher in Sirt1/CD4cre TE recipient group, but this difference did not reach statistical significance (Figure 7f). We observed unusually high CD127 expression in CD4+ Foxp3− iTregs and in host CD4− cells of mice receiving Sirt1/CD4cre TE cells vs. WT TE cells (Figure 5a, b), indicating less proliferation of TE and host cells in recipients of fl-Sirt1/CD4cre TE. CD103 expression in iTregs also tended to be higher in Sirt1/CD4cre TE recipient group, but this difference did not reach statistical significance (Figure 7f).

Loss of Sirt1 in thymic-derived nTregs does not affect rescue from autoimmune colitis

As our data indicated that lack of Sirt1 in TE might predispose them to increased iTreg formation and better outcomes in autoimmune colitis, we considered whether thymic-derived nTregs lacking Sirt1 might exhibit the same advantage. Given that most Tregs in the spleens of young mice are thought to consist of thymic-derived nTregs, we tested whether splenic Tregs were as effective as iTregs in promoting resolution of colitis. We injected WT TE cells intravenously into B6/Rag1−/− mice to induce colitis, and waited for the development of diarrhea and 5–15% weight loss. We then randomized mice into two groups, and injected them with FACS-sorted >95% pure YFP+ Foxp3+ Tregs from fl-Sirt1/Foxp3cre or control Foxp3cre mice. On the basis of our previous work with fl-Sirt1/Foxp3cre mice,13,14 we expected that Sirt1−− nTregs
would have greater suppressive function than WT Tregs. We therefore transferred a suboptimal number of nTregs \((3 \times 10^5)\) to ensure that treatment with control Tregs would be of limited success, so that we could distinguish differential effects of fl-Sirt1/Foxp3cre Treg therapy. As expected, fl-Sirt1/Foxp3cre nTregs showed superior preservation of their Foxp3 expression compared with controls (Figure 8a), consistent with our previous results. However, this did not translate into any better outcome as both treatment groups had comparable weights (Figure 8b), colon lengths (Figure 8c), and cytokine production by CD4\(^+\) TE cells activated with PMA/ionomycin (Figure 8d). Taken together, these results show that the lack of Sirt1 does not make splenic Tregs (presumably mostly nTregs) more suppressive in our autoimmune colitis Treg rescue model.

**Sirt1 inhibition is effective at ameliorating DSS colitis in immunocompetent mice**

Given our findings in the B6/Rag1\(^{-/-}\) adoptive transfer colitis models, we decided to test if these results were translatable into a model closer to potential clinical application. We therefore studied the effects of Sirt1 targeting by pharmacologic inhibition, rather than gene deletion, and used immunocompetent C57BL/6 mice to prevent possible confounding effects arising from the homeostatic proliferation of adoptively transferred cells in immunodeficient mice. We chose to use a chronic colitis model involving multiple repetitive cycles of 5% dextran sodium sulfate (DSS) interchanged with normal drinking water, designed to assess T-helper type 1-based immunopathology. We found that mice treated with the Sirt1 inhibitor EX-527 (1 mg kg\(^{-1}\) per day, intraperitoneally) had less weight loss and rectal bleeding, as well as smaller spleen sizes, than mice receiving vehicle alone (Figure 9a-d). Furthermore, histologic examination of colon samples showed decreased inflammation in the Sirt1 inhibitor-treated group (Figure 9e-g). Among non-T cells, we found that vehicle control-treated animals had more granulocytes and monocytes in their spleens (Figure 9h), showing a trend toward a positive correlation with weight loss (Figure 9i). Similar to the adoptive transfer colitis using TE cells lacking Sirt1, inhibition of Sirt1 increased the number of Foxp3\(^+\) Tregs (Figure 10a). Given the interrelated pathways of iTreg and T-helper type 17 T-cell development and the importance for both cell types in the pathogenesis of autoimmune colitis, we tested if Sirt1 inhibition affected IL-6 or IL-17 production. We did not detect significant differences in IL-6 and IL-17 protein levels in samples from mice receiving Sirt1 inhibitor vs. dimethylsulfoxide (DMSO) (Figure 10b, c). Collectively, our data show that Sirt1 inhibitor treatment can alleviate disease severity in a chronic model of colitis in immunocompetent mice, and consistent with the effects of Sirt1 deletion in adoptive transfer.
models, can promote iTreg formation and ameliorate the development of colitis.

**DISCUSSION**

Immunomodulatory therapy is a promising strategy to limit the burden of IBD. The past two decades have shown remarkable progress in this area, leading to the introduction of innovative therapies into clinical practice. Prominent examples include infliximab, a monoclonal antibody (mAb) against tumor necrosis factor-α, and, more recently, ustekinumab, a mAb against the p40 subunit shared by IL-23 and IL-12. Here, we show that deletion of Sirt1 in CD4⁺Foxp3⁺ TE resulted in markedly reduced colitis in a B6/Rag1⁻/⁻ adoptive transfer model. We observed an increased formation of Tregs in the B6/Rag1⁻/⁻ mice that received fl-Sirt1/CD4cre TE. Through our study design, we ensured that the injected TE cells were depleted for Foxp3⁺ Tregs. Hence, Foxp3⁺ Tregs observed at the end of the experiment were most likely iTregs, which are considered to be critical to the control of IBD pathophysiology. Recently, Karlsson et al. directly compared iTregs to freshly isolated Tregs in controlling autoimmune colitis, and found that iTregs were superior. In contrast to nTregs, which are part of a mechanism to suppress reactions to self-antigen, iTregs develop in response to exogenous antigens in the periphery, consistent with the principle that mucosal surfaces have to encounter and deal with new antigens on an ongoing basis. This fits well with observations that mice incapable of forming iTregs are prone to mucosal, but not other autoimmunity. Given these data, our observation that lack of Sirt1 leads to increased iTreg formation in vivo may be of particular relevance for IBD therapy.

We have previously shown that targeting of Sirt1 does not affect TE cell function or proliferation in vitro or in vivo.

---

**Figure 9**  Sirtuin-1 (Sirt1) inhibition limits severity of dextran sodium sulfate (DSS)-induced colitis and leads to attenuated inflammation. (a) C57Bl/6 mice received three 5-day cycles of 5% DSS challenges followed by a brief 2–3 days recovery. Animals received either the Sirt1 inhibitor EX-527 (1 mg kg⁻¹ per day intraperitoneally) or dimethylsulfoxide (DMSO) vehicle control (n = 18). (b) Limited weight loss was noted in EX-527-treated mice. (c) Spleen sizes appeared slightly enlarged in the control DMSO group. (d) EX-527-treated mice had less rectal bleeding. (e–g) Upon histologic analysis, control animals demonstrate features of severe colitis including (e) marked crypt architectural distortion with neutrophilic infiltration of the lamina propria, crypt epithelium (“cryptitis”), and glandular lumina (“crypt abscess”). Inflammatory changes were ameliorated with the addition of a Sirt1 inhibitor (EX-527). (f) Magnification of area indicated by dashed frame in DMSO treatment group colon specimen from (e). (g) Pooled data from blinded histologic analysis suggest that Sirt1 inhibitor-treated animals had a lower degree of inflammation, intraepithelial lymphocytes, and inflammatory activity. Hematoxylin and eosin staining; bar = 100 μm. (h) Flow cytometry showing decreased CD11b⁺ Gr1hi granulocytes and monocytes in EX-527 recipients (n = 10). (i) Trend toward positive correlation between CD11b⁺ Gr1hi cells and weight loss.
Figure 10  Sirtuin-1 (Sirt1) inhibition promotes induced T-regulatory cell (iTreg) formation, and does not affect interleukin-6 (IL-6) and IL-17 production during dextran sodium sulfate colitis. (a) Sirt1 inhibitor-treated mice exhibited a higher Forkhead box P3-positive Treg among splenocytes, which divided better (Ki-67 expression, right panel), (b and c) Enzyme-linked immunosorbent assay showing (b) IL-6 and (c) IL-17 levels in sera, ileum, and mesenteric lymph node (mLN) from experiments in Figure 6. Data were normalized by square root calculation, as indicated.

Here, we also noted that fl-Sirt1/CD4cre cells were as responsive to Treg-mediated suppression as WT TE cells. However, Foxp3+ Treg numbers and suppressive function are increased by genetic or pharmacologic targeting of Sirt1.13,14 The mechanisms responsible were investigated by us and others.13,14,16–18,30,31 Foxp3 is deacetylated by Sirt1, and Sirt1 inhibition leads to increased Foxp3 acetylation, which makes Foxp3 resistant to proteasomal degradation, and thus stabilizes Foxp3 post-translationally, increasing its quantity.14,16–18,30 In addition, acetylated Foxp3 has enhanced DNA binding to the promoter regions of key transcripts regulated by Foxp3, such as IL-2 and CTLA4.32 Kwon et al.17 have identified three Foxp3 lysine residues, via mass spectrometry, that are subjected to Sirt1-dependent deacetylation (K264, K266, and K268 in human Foxp3), and noted that naive T cells converted more easily to iTregs in vitro when treated with a Sirt1 inhibitor.17 Besides deacetylating Foxp3, Sirt1 deacylates p65, the larger subunit of nuclear factor-kB, which is part of the c-Rel enhanceosome that promotes Foxp3 mRNA expression.32 Preventing Sirt1 from deacetylating p65 at K310 leaves p65 more acetylated, which leads to increased transcriptional activity.33 We have previously shown that Tregs lacking Sirt1 exhibit more p65 K310 acetylation, along with increased p65 nuclear translocation, and more Foxp3 mRNA expression.13,14 Thus, the increase in acetylation of both p65 and Foxp3, as well as an increase in Foxp3 mRNA gene expression as a result of Sirt1 targeting, promote the formation of iTregs.

It is important to note that K310 acetylation and transcriptional activation of p65 can, in some circumstances, also augment inflammation, as illustrated by the effects of myeloid cell-specific deletion of Sirt1.34 Therefore, we considered it essential to assess what happened when normal, immunocompetent animals were treated with a Sirt1 inhibitor and exposed to multiple cycles of DSS challenge. The DSS colitis model is different to the autoimmune colitis in TE-transferred B6/Rag1−/− mice, as it is initiated by nonimmune mechanism of mucosal injury. However, cyclic administration of DSS interchanged with fresh drinking water results in a chronic colitis with a strong T-helper type 1-mediated immune component.21,35 In fact, DSS colitis is also dependent on Foxp3+ Tregs, whose depletion can profoundly worsen colitis and disease outcomes.36 These factors led us to investigate DSS colitis as a model that would (a) investigate mice with normal immune system, and (b) study the global effects of pharmacologic inhibition of Sirt1, as opposed to a targeted genetic deletion. In both adoptive transfer and chronic DSS models, Sirt1 targeting resulted in increased Foxp3+ Treg cell numbers at the end of each experiment, and increased Treg numbers were associated with lower disease activity, better weight preservation, and less lymphoproliferation. Furthermore, we have also looked directly at non-T-cell responses, and noted that both pharmacologic targeting of Sirt1 in the DSS model and the genetic deletion of Sirt1 in the B6/Rag1−/− adoptive transfer colitis model led to reduced granulocyte numbers in the mesenteric lymph nodes of mice subjected to Sirt1 targeting. Of note, murine Tregs have been previously shown to suppress neutrophil accumulation and survival.37,38 Thus, the differences, between DMSO- and Sirt1 inhibitor-treated mice, in disease outcomes and splenic enlargement show that pharmacologic Sirt1 targeting has a net immunosuppressive effect.

In addition to increasing Foxp3+ iTreg numbers, the phenotypic properties of these cells may be important. For example, iTregs arising from fl-Sirt1/CD4cre TE cells tended to have increased expression of CD103 (β2 integrin), which along with integrin β7 is essential for T cells to travel to the intraepithelial space.39 Furthermore, low CD127 expression, shown on Sirt1−/− iTregs in our studies, is associated with improved Foxp3+ Treg-suppressive function in humans.40 As both parameters were correlated with reduced weight loss and attenuated disease, these findings may provide mechanistic clues as to the factors that are most important in iTreg function in the control of IBD.

In conclusion, deletion of Sirt1 alleviates adoptive transfer colitis. Likewise, in WT animals exposed to cyclic DSS challenge, treatment with a Sirt1 inhibitor limits disease severity and weight loss. Our data indicate that, in both cases, the formation of Foxp3+ iTregs is accentuated by Sirt1 targeting, and contributes to a better disease outcome. Therefore, we propose that Sirt1 may be a suitable target in IBD, especially owing to the relative importance of iTregs in controlling immune homeostasis in the gastrointestinal tract.
METHODS

Mice. WT C57BL/6 (CD90.1 and CD90.2) and B6/Rag1−/− (Jackson Laboratory, Bar Harbor, ME), fl-Sirt1/CD4cre, fl-Sirt1/Foxp3cre, and Foxp3cre mice were housed under specific-pathogen-free conditions, and studied using a protocol approved by the Institutional Animal Care and Use Committee of the Children’s Hospital of Philadelphia.

High-purity T-cell isolation. We isolated lymphocytes from spleens and cervical, axillary, and inguinal lymph nodes. After preparing single-cell suspension and cell counting, we used magnetic beads (Miltenyi Biotec, San Diego, CA) to isolate TE (CD4+CD25+), Treg (CD4−CD25+), and CD4+ cells, as well as antigen-presenting cells (CD90.2+). To achieve >98% pure CD4−CD25+Foxp3+ TE cells, a single-cell suspension of lymphocytes were incubated with 1.5 times the recommended amounts of Abs (biotin-conjugated Abs against non-CD4 cells, and Anti-Biotin MicroBeads). Isolation was performed in the dark, the total amount of cells for the LD column was restricted to 1 x 10⁸, and additional LD columns were used if needed. Finally, the purity of isolated cells was documented for each experiment to ensure that data did not result from any differences in TE or Treg purity. For the autoimmune colitis Treg rescue model (Figure 8), we isolated lymphocytes from Foxp3cre and fl-Sirt1/Foxp3cre mice and purified CD4+ cells as above. Then, we sorted CD4 YFP (Foxp3+) Tregs via a FACS Aria cell sorter (BD Biosciences, San Jose, CA; UPenn Cell Sorting Facility).

T-cell function. For assessment of in vitro cytokine production, we incubated freshly isolated TE cells from WT and fl-Sirt1/CD4cre mice overnight (37 °C, 5% CO₂) in 24-well plates precoated with CD3ε and CD28 mAb (2 µg ml⁻¹). In the morning, PMA/ionomycin (Sigma Aldrich, St Louis, MO; cat. nos. P1585-1MG and I0634-1MG) and GolgiStop (BD Biosciences; cat. no. 51-2092kz) were added to reach final concentrations of 30 ng ml⁻¹ PMA, 1 µM ionomycin, and GolgiStop at 0.67µl ml⁻¹ medium. Cells were then incubated for 5 additional hours (37 °C, 5% CO₂), and then harvested for flow cytometry. We used the Fixation/Permeabilization Buffer set from eBioscience (San Diego, CA; cat. no. 88-8823-88) for intranuclear staining. To test TE cells for suppression by Tregs, we used freshly isolated carboxyfluorescein succinimidyl ester-labeled WT and fl-Sirt1/CD4cre TE, with or without WT Tregs, and incubated them for 72 h in the presence of irradiated WT antigen-presenting cells and CD3ε mAb. After 72 h, cells were harvested, labeled with CD4-fluorescent mAb, and analyzed by flow cytometry.

Flow cytometry, Abs, and small molecules. For flow cytometry, we purchased mAbs to murine CD4 (Pacific Blue and APC-H7 from BioLegend (San Diego, CA)), PE-CF594 and APC-Cy7 from BD Pharmingen, San Jose, CA), Ki-67 (PerCP-Cy5.5, clone B56; BD Pharmingen), Foxp3 (PE and eFluor450, clone FJK-16s; eBioscience), CTLA4 (PE; BD Pharmingen), I-A/I-E (FITC; BD Pharmingen), CD11b (APC from eBioscience and PE/Cy7 from BioLegend), Ly-6G (APC; BioLegend), Ly-6C (Pacific Blue; BioLegend), Gr-1 (APC; BioLegend), F4/80 (APC and PE; BioLegend), CD11c (APC/Cy7; BioLegend), CD39 (eFluor 660; eBioscience), CD103 (PE; BioLegend), CD127 (Brilliant Violet421; BioLegend), CCR9 (FITC; BioLegend), and integrin αβ, (APC; BioLegend). For the analysis of mesenteric lymph nodes, we used the Aqua LIVE/DEAD Fixable Dead Cell Stain Kit (Life Technologies, Carlsbad, CA) to exclude false-positive signals from dead and apoptotic cells, and then washed two times before Ab staining. We purchased EX-527 from Tocris Bioscience (Minneapolis, MN). Drugs were dissolved in DMSO, and DMSO was used as a control.

Colitis. We examined three models of colitis. First, in a model involving iTreg formation, 9–10-week-old B6/Rag1−/− mice were adoptively transferred intravenously with 5 x 10⁵ CD4+CD25+Foxp3+ TE cells from either WT or fl-Sirt1/CD4cre mice. Mice were observed for weight, gross blood in their stool, and other clinical parameters as reported previously. In a second model, we adoptively transferred B6/Rag1−/− mice with 5 x 10⁵ CD90.1+CD4+CD25+Foxp3+ TE cells intravenously, and waited for 10 days to let clinically significant colitis develop, with 5–15% of weight loss. We then randomized mice to treatment groups, administered intravenously a suboptimal dose of 3 x 10⁷ FACS-sorted CD4 YFP Foxp3+ Tregs, using Tregs from either fl-Sirt1/Foxp3cre or Foxp3cre (control) mice, and followed the course of colitis, as above. In a third model, we assessed colits induced using 5% DSS (wt vol⁻¹) (molecular weight 36–50 kDa, cat. no. 160110; MP Biomedicals, Solon, OH), and daily administration of either DMSO or EX-527 (1 mg kg⁻¹ per day, intraperitoneally), as reported. In all three models, mice were individually labeled to enable correlation of flow cytometry data with clinical observations. After each experiment, gut and lymphoid tissues were collected for histologic and flow cytometric analysis. For histology, we obtained the entire colon, and for RNA isolation, we used a 2 cm colon piece caudal to the ileocecal junction.

RNA isolation and quantitative PCR. RNA extracted using RNeasy Kits (Qiagen, Valencia, CA) was reverse transcribed to cDNA with random hexamers, and quantified by quantitative polymerase chain reaction as described previously. We used the StepOnePlus real-time PCR system and TaqMan assay reagents (Applied Biosystems, Carlsbad, CA). Differences in cDNA input were corrected by normalizing signals for 18S rRNA. Assessment of inflammatory markers from the colon was normalized against healthy B6/Rag1−/− controls. For some mRNA, such as IL-17, the signal in healthy B6/Rag1−/− mice was too low as these mice lack their own T cells. In those instances, relative expression between control and intervention groups was determined.

Enzyme-linked immunosorbent assay. We obtained 0.5–1 ml blood from cardiac puncture immediately after killing, and isolated the serum. In addition, we collected the supernatants of 2 cm ileum and four mesenteric lymph nodes after being grinded in phosphate-buffered saline. We obtained ELISA Kits (BioLegend) for mouse IL-6 (lot. no. B154708) and IL-17 (lot. no. B152494), and processed according to the manufacturer’s instructions. Plates were read in an iMark Microplate Reader (Bio-Rad, Hercules, CA), Measurements were carried out in duplicate (serum) or triplicate (ileum and mesenteric lymph nodes).

Histology. Segments of bowel that included small intestine, terminal ileum, and colon were fixed in 10% neutral-buffered formalin, paraffin-embedded, and hematoxylin- and eosin-stained sections (4 μm) were reviewed by a pathologist (T.R.B.) blinded to treatment conditions. Histologic findings were characterized using a modification of the scoring systems of Laroux et al. and Aranda et al. to include the following parameters: (1) degree of lamina propria inflammation graded 0–3; (2) degree of mucoin depletion as evidenced by loss of goblet cells graded 0–2; (3) reactive epithelial changes (nuclear hyperchromatism, random nuclear atypia, increased mitotic activity) graded 0–3; (4) number of intraepithelial lymphocytes per high-power field within crypts graded 0–3; (5) degree of crypt architectural distortion graded 0–3; (6) degree of inflammatory activity (infiltration of neutrophils within lamina propria and crypt epithelium, “cryptitis”) graded 0–2; (7) degree of transmural inflammation graded 0–2; and (8) degree of mucosal surface erosion up to total surface ulceration graded 0–2. The total histopathologic score was determined from the sum of the scores for each parameter to reflect the overall degree of inflammation within each specimen.

Immunohistochemistry. Immunohistochemistry of paraffin-embedded sections, prepared as above, was performed with primary Abs to CD3 (Dako, Carpinteria, CA; A0452; 1:100) with DAB (Dako Cytomation), Immunostained slides were scanned using the Aperio ScanScope C5 slide scanner (Aperio Technologies, Vista, CA). Whole slide digitized images were analyzed using the Aperio ImageScope.
software (version 10.0.1346.1807: Aperio Technologies) for determination of the percentage of cells with membranous decoration for CD3 from the total number of cells present on the slide. Only cells with high 3+ intensity of staining were selected for analysis.

**Statistical analysis.** Data were analyzed using GraphPad Prism 5.0d software (La Jolla, CA). All data were tested for normal distribution of variables, and normally distributed data were displayed as mean ± s.e.m. Enzyme-linked immunosorbent assay data were normalized using square root calculations. Comparisons between two groups were assessed with a Student’s t-test if normally distributed, or Mann–Whitney U-test if otherwise. Likewise, groups of three or more were analyzed by one-way analysis of variance if normally distributed, or the Kruskal–Wallis test if not. For correlation, we used Pearson’s correlation for normally distributed data.

**SUPPLEMENTARY MATERIAL** is linked to the online version of the paper at http://www.nature.com/mi

**ACKNOWLEDGMENTS**

This project was supported by Award Number K08AI095353 (to U.H.B.), AI073489, and AI099576 (to W.W.H.) from the National Institute of Allergy and Infectious Diseases. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. We thank Benjamin L. Laskin for proofreading our manuscript.

**AUTHORS CONTRIBUTION**

U.H.B. and W.W.H. conceived the project and developed the experimental design. U.H.B., T.A., H.X., L.W., R.H., and K.Z contributed the data. U.H.B., T.A., T.R.B., L.W., R.H., and K.Z contributed the data. U.H.B., T.A., Y.L., T.R.B., E.E., S.S., and W.W.H. analyzed the data. U.H.B. and T.A. wrote the paper. W.W.H. edited the paper.

**DISCLOSURE**

The authors declare no conflict of interest.

© 2014 Society for Mucosal Immunology

**REFERENCES**

1. Macdonald, T.T. & Monteleone, G. Immunity, inflammation, and allergy in the gut. *Science* **307**, 1920–1925 (2005).

2. Izcuc, A., Coombes, J.L. & Powrie, F. Regulatory lymphocytes and intestinal inflammation. *Annu Rev Immunol* **27**, 313–338 (2009).

3. Himmel, M.E., Yao, Y., Orban, P.C., Steiner, T.S. & Levings, M.K. Regulatory T-cell therapy for inflammatory bowel disease: more questions than answers. *Immunity* **136**, 115–122 (2012).

4. Curotto de Lafaille, M.A. & Lafaille, J.J. Natural and adaptive foxp3+ regulatory T cells: more of the same or a division of labor? *Immunity* **30**, 626–639 (2009).

5. Hori, S., Nomura, T. & Sakaguchi, S. Control of regulatory T cell development by the transcription factor Foxp3. *Science* **299**, 1057–1061 (2003).

6. Fontenot, J.D., Gavin, M.A. & Rudensky, A.Y. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. *Nat Immunol* **4**, 330–336 (2003).

7. Bennett, C.L. et al. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. *Nat Genet* **27**, 20–21 (2001).

8. Wang, Y., Liu, X.P., Zhao, Z.B., Chen, J.H. & Yu, C.G. Expression of CD4+forkhead box P3 (FOXP3)+ regulatory T cells in inflammatory bowel disease. *J Dig Dis* **12**, 286–294 (2011).

9. Ban, H., Andoh, A., Shioya, M., Nishida, A., Tsujikawa, T. & Fujiyama, Y. Increased number of Foxp3+CD4+ regulatory T cells in inflammatory bowel disease. *Mol Med Rep* **1**, 647–650 (2008).

10. Bilate, A.M. & Lafaille, J.J. Induced CD4+Foxp3+ regulatory T cells in immune tolerance. *Annu Rev Immunol* **30**, 733–758 (2012).

11. Josefowicz, S.Z. et al. Extrathymically generated regulatory T cells control mucosal TH2 inflammation. *Nature* **482**, 595–599 (2012).

12. Schienner, S.M., Weigmann, B., Ruan, Q., Chen, Y. & von Boehmmer, H. Smad3 binding to the foxp3 enhancer is dispensable for the development of regulatory T cells with the exception of the gut. *J Exp Med* **209**, 1529–1535 (2012).

13. Beier, U.H. et al. Sirtuin-1 targeting promotes Foxp3+ T-regulatory cell function and prolongs aloagraft survival. *Mol Cell Biol* **31**, 1022–1029 (2011).

14. Beier, U.H., Wang, L., Han, R., Akimova, T., Liu, Y. & Hancock, W.W. Histone deacetylases 6 and 9 and sirtuin-1 control Foxp3 + regulatory T cell function through shared and isoform-specific mechanisms. *Sci Signal* **5**, ra45 (2012).

15. Houtkooper, R.H., Pirinen, E. & Auwerx, J. Sirtuins as regulators of metabolism and healthspan. *Nat Rev Mol Cell Biol* **13**, 225–238 (2012).

16. van Loosdregt, J., Brunen, D., Fleksens, V., Pals, C.E., Lam, E.W. & Cofer, P.J. Rapid temporal control of Foxp3 protein degradation by sirtuin-1. *PLoS One* **6**, e19047 (2011).

17. Kwon, H.S., Lim, H.W., Wu, J., Schnolzer, M., Verdin, E. & Ott, M. Three novel acetylation sites in the Foxp3 transcription factor regulate the suppressive activity of regulatory T cells. *J Immunol* **188**, 2712–2721 (2012).

18. Beier, U.H., Akimova, T., Liu, Y., Wang, L. & Hancock, W.W. Histone/protein deacetylases control Foxp3 expression and the heat shock response of T-regulatory cells. *Curr Opin Immunol* **23**, 670–678 (2011).

19. Josefowicz, S.Z., Lu, L.F. & Rudensky, A.Y. Regulatory T cells: mechanisms of differentiation and function. *Annu Rev Immunol* **30**, 531–564 (2012).

20. Scholzen, T. & Gerdes, J. The Ki-67 protein: from the known and the unknown. *J Cell Physiol* **182**, 311–322 (2000).

21. Okayasu, I., Hatakeyama, S., Yamada, M., Ohkusa, T., Inagaki, Y. & Nakaya, R. A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. *Gastroenterology* **98**, 694–702 (1990).

22. Veldhoen, M., Hocking, R.J., Atkins, C.J., Locksley, R.M. & Stockinger, B. TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. *Immunity* **24**, 179–189 (2006).

23. Abraham, C. & Cho, J.H. Inflammatory bowel disease. *N Engl J Med* **361**, 2066–2078 (2009).

24. Rutgeerts, P., Van Assche, G. & Vermeire, S. Review article: infliximab therapy for inflammatory bowel disease—seven years on. *Aliment Pharmacol Ther* **23**, 451–463 (2006).

25. Sandboorn, W.J. et al. Ustekinumab induction and maintenance therapy in refractory Crohn’s disease. *N Engl J Med* **367**, 1519–1528 (2012).

26. Boden, E.K. & Snapper, S.B. Regulatory T cells in inflammatory bowel disease. *Curr Opin Gastroenterol* **24**, 733–741 (2008).

27. Karlsson, F., Martinez, N.E., Gray, L., Zhang, S., Tsunoda, I. & Grisham, M.B. Therapeutic evaluation of ex vivo-generated versus natural regulatory T-cells in a mouse model of chronic gut inflammation. *Inflamm Bowel Dis* **19**, 2282–2294 (2013).

28. Workman, C.J., Szymczak-Workman, A.L., Collison, L.W., Pillai, M.R. & Vignali, D.A. The development and function of regulatory T cells. *Cell Mol Life Sci* **66**, 2003–2022 (2009).

29. Weiner, H.L., da Cunha, A.P., Quintana, F. & Wu, H. Oral tolerance. *Immuno Rev* **241**, 241–259 (2011).

30. van Loosdregt, J. et al. Regulation of Treg functionality by acetylation-mediated Foxp3 protein stabilization. *Blood* **115**, 965–974 (2010).

31. Liu, Y., Wang, L., Han, R., Beier, U.H. & Hancock, W.W. Two lysines in the forkhead domain of foxp3 are key to Tregulatory cell function. *PLoS One* **7**, e29035 (2012).

32. Ruan, Q. et al. Development of Foxp3(+) regulatory T cells is driven by the NF-κB enhancer. *Immunity* **31**, 932–940 (2009).

33. Chen, L.F., Mu, Y. & Greene, W.C. Acetylation of Rela at discrete sites regulates distinct nuclear functions of NF-κbappaB. *EMBO J* **20**, 6539–6548 (2002).

34. Schug, T.T. et al. Myeloid deletion of SIRT1 induces inflammatory signaling in response to environmental stress. *Mol Cell Biol* **30**, 4712–4721 (2010).

35. Perse, M. & Cesar, A. Dextran sodium sulphate colitis mouse model: traps and tricks. *J Biomed Biotechnol* **2012**, 718617 (2012).

36. Boehm, F. et al. Deletion of Foxp3+ regulatory T cells in genetically targeted mice supports development of intestinal inflammation. *BMC Gastroenterol* **12**, 9 (2012).
37. Richards, H. et al. Novel role of regulatory T cells in limiting early neutrophil responses in skin. *Immunology* **131**, 583–592 (2010).

38. Lee, D.C. et al. CD25+ natural regulatory T cells are critical in limiting innate and adaptive immunity and resolving disease following respiratory syncytial virus infection. *J Virol* **84**, 8790–8798 (2010).

39. Shibahara, T., Si-Tahar, M., Shaw, S.K. & Madara, J.L. Adhesion molecules expressed on homing lymphocytes in model intestinal epithelia. *Gastroenterology* **118**, 289–298 (2000).

40. Liu, W. et al. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. *J Exp Med* **203**, 1701–1711 (2006).

41. Rubtsov, Y.P. et al. Regulatory T cell-derived interleukin-10 limits inflammation at environmental interfaces. *Immunity* **28**, 546–558 (2008).

42. de Zoeten, E.F., Wang, L., Sai, H., Dillmann, W.H. & Hancock, W.W. Inhibition of HDAC9 increases T regulatory cell function and prevents colitis in mice. *Gastroenterology* **138**, 583–594 (2010).

43. Laroux, F.S. et al. Regulation of chronic colitis in athymic nu/nu (nude) mice. *Int Immunol* **16**, 77–89 (2004).

44. Aranda, R. et al. Analysis of intestinal lymphocytes in mouse colitis mediated by transfer of CD4+, CD45RBhigh T cells to SCID recipients. *J Immunol* **158**, 3464–3473 (1997).